AbbVie-Allergan in India – Brimming With Opportunities?

Allergan brings with it a market-leading ophthalmology franchise and promising prospects for Botox in India, opening up new avenues for growth for AbbVie, which so far has been measured compared with some multinational peers in the country.

Puzzle
AbbVie-Allergan Have Multiple Growth Avenues In India

AbbVie Inc. may so far have been playing on the fringes of the Indian market, but its planned $63bn acquisition of Allergan PLC will give it a market-leading presence in the ophthalmology segment in the country and offers significant potential to expand the Botox business, among other growth avenues.

Unusually, AbbVie does not sell its crown jewel Humira (adalimumab) at all in India and only has a small basket...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip